[
  {
    "ts": null,
    "headline": "Sell Novo Nordisk And Buy Viking Therapeutics",
    "summary": "Discover top obesity drug stocks: Why LLY and VKTX outshine Novo Nordisk (NVO) for long-term gains.",
    "url": "https://finnhub.io/api/news?id=eb8c6a8ccab9704c57f8dec215e057226204d2d5938f59bec35f090944614ae3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762121705,
      "headline": "Sell Novo Nordisk And Buy Viking Therapeutics",
      "id": 137299553,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157582285/image_157582285.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover top obesity drug stocks: Why LLY and VKTX outshine Novo Nordisk (NVO) for long-term gains.",
      "url": "https://finnhub.io/api/news?id=eb8c6a8ccab9704c57f8dec215e057226204d2d5938f59bec35f090944614ae3"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Loom; Palantir, Robinhood Lead Earnings",
    "summary": "The stock market has continued to climb, but it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.",
    "url": "https://finnhub.io/api/news?id=4b763728c9182c390ba2d7efcfdcfbb82cd266abb5ec7215438813c5fba0cad7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762105872,
      "headline": "Dow Jones Futures Loom; Palantir, Robinhood Lead Earnings",
      "id": 137294495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock market has continued to climb, but it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.",
      "url": "https://finnhub.io/api/news?id=4b763728c9182c390ba2d7efcfdcfbb82cd266abb5ec7215438813c5fba0cad7"
    }
  },
  {
    "ts": null,
    "headline": "Rethinking Your Portfolio: The Stocks That Could Outperform for Years",
    "summary": "Now is a great time to be shopping for stocks that can anchor your portfolio.",
    "url": "https://finnhub.io/api/news?id=ae61100e0eebbb9e0dae7c663c85826e0b80364f77a19aa09531181ddcd29021",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762099080,
      "headline": "Rethinking Your Portfolio: The Stocks That Could Outperform for Years",
      "id": 137294496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Now is a great time to be shopping for stocks that can anchor your portfolio.",
      "url": "https://finnhub.io/api/news?id=ae61100e0eebbb9e0dae7c663c85826e0b80364f77a19aa09531181ddcd29021"
    }
  },
  {
    "ts": null,
    "headline": "Why The Story Around Eli Lilly Is Evolving After Recent Analyst Updates and Company News",
    "summary": "Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward revision follows robust quarterly performance and optimism for future revenue growth, even as projections have moderated slightly. Stay tuned to discover how ongoing developments and shifting analyst views will continue to shape perspectives on Eli Lilly’s stock narrative. Analyst Price Targets don't...",
    "url": "https://finnhub.io/api/news?id=e21ee6ad8ee21c51f6d1881931d4dbf9ee219a21f522de3e15d8e1304eedd823",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762092696,
      "headline": "Why The Story Around Eli Lilly Is Evolving After Recent Analyst Updates and Company News",
      "id": 137294497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward revision follows robust quarterly performance and optimism for future revenue growth, even as projections have moderated slightly. Stay tuned to discover how ongoing developments and shifting analyst views will continue to shape perspectives on Eli Lilly’s stock narrative. Analyst Price Targets don't...",
      "url": "https://finnhub.io/api/news?id=e21ee6ad8ee21c51f6d1881931d4dbf9ee219a21f522de3e15d8e1304eedd823"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next",
    "summary": "Eli Lilly and Company ( NYSE:LLY ) defied analyst predictions to release its quarterly results, which were ahead of...",
    "url": "https://finnhub.io/api/news?id=bb1111ca1ccba2cee2c8b70eb4b998e89e77ec668ec53f4d5b0855b53a9c4bbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762087510,
      "headline": "Eli Lilly and Company Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next",
      "id": 137294498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company ( NYSE:LLY ) defied analyst predictions to release its quarterly results, which were ahead of...",
      "url": "https://finnhub.io/api/news?id=bb1111ca1ccba2cee2c8b70eb4b998e89e77ec668ec53f4d5b0855b53a9c4bbf"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk",
    "summary": "Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.",
    "url": "https://finnhub.io/api/news?id=28f2b8110e3b07169ad95c96e9161ccd4673fa0d3ee31319e14b017d2ea4f3cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762079400,
      "headline": "Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk",
      "id": 137294499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.",
      "url": "https://finnhub.io/api/news?id=28f2b8110e3b07169ad95c96e9161ccd4673fa0d3ee31319e14b017d2ea4f3cb"
    }
  }
]